Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients

Read

Sensorion Amends Existing Convertible Notes Program Under More Favorable Terms with €10 Million in Financing

Read

Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved

Read

Sensorion takes a key step towards phase 2 with SENS-401 thanks to the positive results obtained in the phase 1 clinical trial

Read

Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model

Read

Pipeline

2018 08 Pipeline

Enregistrer

Patient center

Corporate presentation

Next events